资讯

BioPharma Dive51 分钟

PTC drug for Friedrich’s ataxia rejected; Lilly sells nearly $7B in bonds

The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on ...